Compare · ANTM vs BDSX
ANTM vs BDSX
Side-by-side comparison of Anthem Inc. (ANTM) and Biodesix Inc. (BDSX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTM and BDSX operate in Medical Specialities (Health Care), so they compete in similar markets.
- ANTM is the larger of the two at $107.30B, about 671.1x BDSX ($159.9M).
- BDSX has hit the wire 6 times in the past 4 weeks while ANTM has been quiet.
- ANTM has more recent analyst coverage (25 ratings vs 7 for BDSX).
- Company
- Anthem Inc.
- Biodesix Inc.
- Price
- $482.32+2.61%
- $15.29-0.20%
- Market cap
- $107.30B
- $159.9M
- 1M return
- -
- +34.95%
- 1Y return
- -
- +154.83%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- News (4w)
- 0
- 6
- Recent ratings
- 25
- 7
Anthem Inc.
Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through four segments: Commercial & Specialty Business, Government Business, IngenioRx, and Other. The company offers a spectrum of network-based managed care health benefit plans to large and small groups, individuals, Medicaid, and Medicare markets. Its managed care plans include preferred provider organizations; health maintenance organizations; point-of-service plans; traditional indemnity plans and other hybrid plans, including consumer-driven health plans; and hospital only and limited benefit products. The company also provides a range of managed care services to self-funded customers, including claims processing, underwriting, stop loss insurance, actuarial services, provider network access, medical cost management, disease management, wellness programs, and other administrative services. In addition, it offers an array of specialty and other insurance products and services, such as pharmacy benefits management, dental, vision, life and disability insurance benefits, radiology benefit management, and analytics-driven personal health care. Further, the company provides services to the federal government in connection with the Federal Employee Program; and operates as a licensee of the Blue Cross and Blue Shield Association. As of December 31, 2020, it served 43 million medical members through its affiliated health plans. The company was formerly known as WellPoint, Inc. and changed its name to Anthem, Inc. in December 2014. Anthem, Inc. was founded in 1944 and is headquartered in Indianapolis, Indiana.
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Latest ANTM
- SEC Form 4: Todt Blair Williams was granted 3,983 shares, increasing direct ownership by 93% to 8,283 units
- SEC Form 4: Norwood Felicia F covered exercise/tax liability with 1,754 shares, decreasing direct ownership by 6% to 26,684 units
- SEC Form 4: Todt Blair Williams covered exercise/tax liability with 117 shares, decreasing direct ownership by 3% to 4,300 units
- SEC Form 4: Boudreaux Gail gifted 10,000 shares, decreasing direct ownership by 8% to 111,415 units
- Anthem Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4: Kendrick Charles Morgan Jr covered exercise/tax liability with 79 shares, decreasing direct ownership by 0.54% to 14,450 units
- SEC Form 4: Haytaian Peter D covered exercise/tax liability with 200 shares, decreasing direct ownership by 2% to 11,961 units
- SEC Form 4: Strable-Soethout Deanna D was granted 200 shares
- SEC Form 3 filed by new insider Strable-Soethout Deanna D
- SEC Form 424B3 filed by Anthem Inc.
Latest BDSX
- SEC Form EFFECT filed by Biodesix Inc.
- SEC Form S-3 filed by Biodesix Inc.
- Biodesix to Participate in Upcoming Investor Conferences
- SEC Form 8-K filed by Biodesix Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biodesix Inc.
- Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces First Quarter 2026 Results and Highlights
- SEC Form SCHEDULE 13G filed by Biodesix Inc.